97,722 Shares in Vor Biopharma Inc. $VOR Purchased by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon bought 97,722 Vor Biopharma shares worth approximately $1.8 million, giving it a 0.18% stake. Institutional investors collectively own 97.29% of the company.
• Analyst sentiment is generally positive, with Vor Biopharma holding a consensus “Moderate Buy” rating and an average price target of $43.38. Recent target changes included Wedbush raising its target to $27, while HC Wainwright maintained a $31 “Buy” target.
• Vor Biopharma opened at $25.10, above its 50-day and 200-day moving averages, but its latest quarterly loss of $0.80 per share missed estimates of $0.69; analysts expect a full-year loss of $2.56 per share.

Bank of New York Mellon Corp purchased a new stake in shares of Vor Biopharma Inc. (NASDAQ:VOR - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 97,722 shares of the company's stock, valued at approximately $1,799,000. Bank of New York Mellon Corp owned 0.18% of Vor Biopharma at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the period. Jane Street Group LLC bought a new stake in Vor Biopharma in the first quarter valued at $140,000. XTX Topco Ltd purchased a new position in Vor Biopharma during the 2nd quarter valued at $66,000. BNP Paribas Financial Markets increased its position in Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company's stock valued at $296,000 after purchasing an additional 5,058 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Vor Biopharma in the 3rd quarter worth $230,000. Institutional investors own 97.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $31.00 price target on shares of Vor Biopharma in a research note on Monday, May 18th. Wall Street Zen raised Vor Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Wedbush upped their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th. Finally, Weiss Ratings upgraded Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Vor Biopharma currently has a consensus rating of "Moderate Buy" and an average price target of $43.38.

Vor Biopharma Price Performance

Shares of NASDAQ VOR opened at $25.10 on Wednesday. Vor Biopharma Inc. has a 1 year low of $6.50 and a 1 year high of $49.95. The firm has a 50-day moving average of $21.55 and a 200 day moving average of $17.27.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). On average, equities analysts forecast that Vor Biopharma Inc. will post -2.56 EPS for the current year.

Vor Biopharma Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

Want to see what other hedge funds are holding VOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vor Biopharma Inc. (NASDAQ:VOR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.